Investigation of recurrence detection in vulva cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore various aspects of recurrence detection in women diagnosed with vulva cancer. It is a nationwide multicenter initiative in Denmark that will collect patient-reported outcomes and procedural data to evaluate symptoms and actions taken from the initial diagnosis to recurrence. Additionally, the study will investigate the presence of circulating tumor-DNA in liquid biopsies from patients. Participants will be monitored for two years or until recurrence, with regular assessments every four months.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Primary or recurrent biopsy-verified squamous cell carcinoma of the vulva
* ≥ 18 years of age
* Able to understand oral and written information in Danish

Exclusion Criteria:

* Active treatment for concurrent cancer and/or dissemination of concurrent cancer

Where it's running

• Aarhus University Hospital
  Aarhus N, Denmark Recruiting
• Copenhagen University Hospital
  Copenhagen, Denmark Recruiting

Study contacts

• Principal investigator: Pernille T. Jensen, Professor — Aarhus University Hospital
• Study coordinator: Louise Krog, BSc.med.
• Email: loukrg@rm.dk
• Phone: 20995607

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment with STAR0602 for advanced solid tumors

  This study is testing a new treatment called STAR0602 to see if it can help people with advanced solid tumors by looking at how safe it is and how well it works.

  Recruiting at 16 sites Phase 1/2 Marengo Therapeutics, Inc. · Sacramento, California and 18 other locations · NCT05592626

• Methylation markers in self-samples to help detect gynecological cancers

  This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.

  Recruiting Universiteit Antwerpen · Edegem, Antwerp · NCT07902375

• Radiotherapy for gynecologic cancer with up to 10 metastatic sites

  This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość · NCT07883798

• Cognitive training with real-time brain feedback for childhood medulloblastoma survivors

  This study tests whether real-time brain feedback using rt-fMRI or rt-fNIRS can help children and young adults who survived childhood medulloblastoma improve attention and working memory.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07830134

• Vaginitis Diagnostic Algorithm Pilot Using Nanopath and Other Tests

  This study tests a new Nanopath vaginal test to see if it correctly detects vaginitis-causing pathogens in up to 1,000 people with vaginitis symptoms.

  Recruiting at 2 sites Nanopath, Inc · North Miami, Florida and 1 other locations · NCT07607470

• Hematologic cancer survivors after stem cell transplant try a personalized care plan

  This study tests a personalized Survivorship Care Plan for people with hematologic cancer who have undergone a stem cell transplant to see if it’s feasible within the Italian health system.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia · NCT07579065

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.